Wyeth

American Cyanamid Company

Wyeth Holdings Corporation

Pfizer Corporation

Semiramis Ayral-Kaloustian

Arie Zask

Joshua Aaron Kaplan

David James Richard

Kevin Joseph Curran

Jeroen Cunera Verheijen

Aranapakam Mudumbai Venkatesan

Christoph Martin Dehnhardt

Ariamala Gopalsamy

Tarek Suhayl Mansour

Efren Guillermo Delos Santos

Osvaldo Dos Santos

Mengxiao Shi

Zecheng Chen

Joseph William Epstein

Mila T Du

James J Gibbons, Jr

Steven R Schow

Gary Harold Birnberg

Nan Zhang

Middleton B Floyd, Jr

Vern G DeVries

Thomas H Claus

Edward James Salaski

Vincent Premaratna Sandanayaka

Yanzhong Wu

Ayako Yamashita

Philip Ross Hamann

Emily B Norton

Chuan S Niu

Thai Nguyen

Gloria Jean Macewan

Katherine Cheung

Kinwang Cheung

Ronald Suayan

Scott Christian Mayer

Middleton Brawner Floyd

Hwei-Ru Tsou

David Michael Blum

Xiaoxiang Liu

Douglas Bruce Kitchen

Jean Schmid

Kristina Martha Kutterer

Andrei Shavnya

Annette L Banker

Irwin J Hollander

Jay Thomas Afragola

Zhilian Tang

Ramaswamy Nilakantan

Wei Tong

Tritin Tran

Ann Aulabaugh

Mercy Adufa Otteng

Marvin Reich

Christoph M Dehnhardt

Jeroen C Verheijen

Compounds of formula I  and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

Triazine compounds as PI3 kinase and mTOR inhibitors

Triazine compounds as P13 kinase and MTOR inhibitors

Compounds of formula I wherein:Ris and R, R, and Rare defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.

The invention relates to thienopyrimidine and pyrazolopyrimidine compounds of the Formulas (Ia) and (IIa), or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein compositions comprising the compounds, and methods for making and using the compounds.

Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors

This invention relates to methods for treating or inhibiting cancers in a mammal in need thereof, which comprises administering an effective amount of a 6-Aryl-7-halo-imidazo[1,2 -a]pyrimidine compound of the formula: or pharmaceutically acceptable salts thereof.

6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents

This invention provides compounds of Formula (I), having the structure 

[object Object]

The invention provides compounds of formula (I): wherein E, A, B', R, R, R, and Rare defined in the specification which compounds exhibit anticancer activity and are useful for treating cancer.

Compounds for treating tumors

This invention relates to certain 5-arylpyrimidine compounds or a pharmaceutically acceptable salt thereof, and compositions containing said compounds or a pharmaceutically acceptable salt thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

5-arylpyrimidines as anticancer agents

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

6-[(substituted)phenyl]triazolopyrimidines as anticancer agents

The present invention provides a process for the preparation of 6-[(substituted)phenyl]-triazolopyrimidine dicarboxylic acid salt and as a hydrated salt having the structural formula (I) wherein:

Process for the preparation of tubulin inhibitors

Growing community of inventors

Tarrytown, NY, United States of America

Semiramis Ayral-Kaloustian